Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Difficulty swallowing and lack of receipt of highly active antiretroviral therapy predict acute weight loss in human immunodeficiency virus disease.

Jacobson DL, Bica I, Knox TA, Wanke C, Tchetgen E, Spiegelman D, Silva M, Gorbach S, Wilson IB.

Clin Infect Dis. 2003 Nov 15;37(10):1349-56.

PMID:
14583869
2.
3.

Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003.

Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke C.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):70-6.

PMID:
16123685
4.

Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL.

Clin Infect Dis. 2000 Sep;31(3):803-5.

PMID:
11017833
5.

Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.

Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C.

Clin Infect Dis. 2007 Jan 15;44(2):295-300.

PMID:
17173234
6.

Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients.

Fernández Cotarelo MJ, Abellán Martínez J, Guerra Vales JM, Martínez Sánchez P, Rodrigo Gómez De La Bárcena M, Salto Fernández E.

Clin Infect Dis. 2003 Oct 1;37(7):973-7.

PMID:
13130410
7.

Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.

Maia BS, Engelson ES, Wang J, Kotler DP.

Clin Nutr. 2005 Dec;24(6):971-8.

PMID:
16095765
8.

Understanding the role of HIV load in determining weight change in the era of highly active antiretroviral therapy.

Mwamburi DM, Wilson IB, Jacobson DL, Spiegelman D, Gorbach SL, Knox TA, Wanke CA.

Clin Infect Dis. 2005 Jan 1;40(1):167-73.

PMID:
15614708
9.

[Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].

Neumann T, Kondratieva J, Eggebrecht H, Wieneke H, Esser S, Bartel T, Erbel R.

Herz. 2005 Sep;30(6):504-9. Review. German.

PMID:
16170681
10.

Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Grau I, Pallares R, Tubau F, Schulze MH, Llopis F, Podzamczer D, Liñares J, Gudiol F; Spanish Pneumococcal Infection Study Network (G03/103)..

Arch Intern Med. 2005 Jul 11;165(13):1533-40.

PMID:
16009870
11.

High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection.

Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, Margolick JB.

Pharmacotherapy. 2006 May;26(5):674-81.

PMID:
16637796
13.
14.

Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.

Ramírez-Amador V, Ponce-de-León S, Anaya-Saavedra G, Crabtree Ramírez B, Sierra-Madero J.

Clin Infect Dis. 2007 Oct 1;45(7):925-32.

PMID:
17806063
15.

Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study.

Mussi-Pinhata MM, Rego MA, Freimanis L, Kakehasi FM, Machado DM, Cardoso EM, Read JS; NISDI Perinatal Protocol Study Group..

Pediatr Infect Dis J. 2007 Nov;26(11):1032-7.

PMID:
17984811
16.

HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy.

Campa A, Yang Z, Lai S, Xue L, Phillips JC, Sales S, Page JB, Baum MK.

Clin Infect Dis. 2005 Oct 15;41(8):1179-85.

PMID:
16163638
17.

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.

O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P.

J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):407-14.

PMID:
14615659
18.

HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank.

Morgello S, Estanislao L, Simpson D, Geraci A, DiRocco A, Gerits P, Ryan E, Yakoushina T, Khan S, Mahboob R, Naseer M, Dorfman D, Sharp V; Manhattan HIV Brain Bank..

Arch Neurol. 2004 Apr;61(4):546-51.

PMID:
15096404
19.

Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.

Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Solinas P, Mannazzu M, Falchi A, Mura MS, Madeddu G.

Clin Endocrinol (Oxf). 2006 Apr;64(4):375-83.

PMID:
16584508
20.

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.

Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323.

PMID:
18294112

Supplemental Content

Support Center